Director, Global RWE-HO, Oncology

Position Summary

For drugs to be successful, there must be robust health outcomes data to support launch optimization, reimbursement and maintain market positioning. Specifically, evidence must be generated and maintained throughout the product lifecycle as the standard of care changes, new competitors are introduced, and patents expire on existing competitors. The landscape is evolving quickly as trials demonstrating efficacy in an area of unmet need may receive expedited review or orphan product status designation, which affects both GSK and competitors launch timelines and approval requirements.

More of our customers are developing sophisticated internal health outcomes capabilities and access to real world data that can be used to better understand unmet needs and real‑world effectiveness of our medicines. We need to better understand how our customers define value and to effectively collaborate with them to ensure we are generating value evidence data that includes real world evidence and cost effectiveness analyses that are impactful for payers, health systems, providers, and patients.

This role will report directly into the Senior Director, Global Real‑World Evidence & Health Outcomes Data Generation Lead for a complex priority asset, will have expertise in real‑world evidence and other non‑interventional study methods, and will be a key member of the asset team and other relevant matrix leadership teams. The Director, Global Real‑World Evidence & Health Outcomes Scientist will be accountable for engaging closely with medical and matrix stakeholders and partnering effectively in data generation plan (DGP) planning, design, execution, translation and dissemination at the study level for the asset.

• Plan, design and execute multiple studies for a given asset and manage timelines, deliverables, and budget.
• Assure quality of deliverables, including review and sign off project specifications, protocols, data analysis plans, final study reports, abstracts, posters and manuscripts, in adherence to SOPs.
• Identify resources, references and analyses to inform scientific design and advise internal experts (medical affairs, clinical, commercial/market access) and external experts as needed in support of the asset team.
• Translate needs for evidence into study concepts in alignment with strategic objectives and vision for the asset, e.g. development of study protocols and proposing innovative and cost‑effective ways of developing and executing studies.
• Develop and maintain a good working knowledge of real‑world data resources, existing partnerships and public initiatives and become the point person for select sources to advise on their suitability to address given research questions.
• Develop a deep understanding of customers’ needs, including clinicians and HTA requirements, and their acceptance of different types of evidence and impact of that evidence to their decision making.
• Collaborate with internal teams and participate in best practice sharing sessions across the non‑interventional study organization.
• Build strong working relationships with stakeholder groups across medical, market access, R&D and commercial to ensure strategic alignment and optimal cross‑functional collaboration and communication.
• Ensure key stakeholders, including TA aligned business leaders, are regularly updated on plans through periodic reporting.
• Develop excellent working relationships with external thought leaders to ensure appropriate methods and research agendas are applied, in accordance with GSK policies.

• MSc, or equivalent in health outcomes, health economics, epidemiology, pharmacy, health or life sciences.
• 3+ years of experience working in the pharmaceutical industry, preferably in a multi‑national company.
• Experience in planning and delivering individual projects, managing budgets and working within a matrix setting.
• A history of designing a variety of RWE studies including prospective observational studies, cross‑sectional and retrospective cohort studies, chart reviews, and database analyses.
• Proficiency in utilizing evidence for the development of HTA submissions, reimbursement and/or…